abstract |
The present invention relates to tricyclic heteroaryl compounds that serve as effective phosphodiesterase (PDE) inhibitors. The present invention also relates to compounds that are selective inhibitors of PDE10. The invention further relates to pharmaceutical compositions comprising such compounds, the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention also relates to a method for treating neurodegeneration and psychiatric disorders, such as disorders including psychosis and undercognition as symptoms. |